최봉금 (성균관대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회329

최봉금Bongkum Choi

성균관대학교 의과대학

Biomater. Res., May 31 2024, 12 (1) | https://doi.org/10.1186/s40364-024-00604-x PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals

Ji Young Kim^1†, Ji Hye Shin^1†, Mi-Jeong Kim^1†, Bongkum Choi^2,3†, Yeeun Kang¹, Jimin Choi⁴, Seo Hyun Kim¹, Dohee Kwan³, Duk-Hwan Kim², Eunyoung Chun^5*and Ki-Young Lee^1,4,6*

¹Department of Immunology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419, Republic of Korea

²Department of Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea

³Bioanalysis Center, GenNBio Inc., Seongnam, Republic of Korea

⁴Department of Metabiohealth, Sungkyun Convergence Institute, Sungkyunkwan University, Suwon, Republic of Korea

⁵Research and Development Center, CHA Vaccine Institute, 560 Dunchondaero, Jungwon-gu, Seongnam-si, Gyeonggi-do 13230, Republic of Korea

⁶Department of Health Science and Technology, Samsung Medical Center, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

^†Ji Young Kim, Ji Hye Shin, Mi-Jeong Kim and Bongkum Choi contributed equally to this work.

^*Correspondence: Eunyoung Chun, Ki-Young Lee

Abstract

Protein tyrosine kinase 2 (PTK2), epidermal growth factor receptor (EGFR), and toll-like receptor (TLRs) are amplified in non-small cell lung cancer (NSCLC). However, the functional and clinical associations between them have not been elucidated yet in NSCLC. By using microarray data of non-small cell lung cancer (NSCLC) tumor tissues and matched normal tissues of 42 NSCLC patients, the genetic and clinical associations between PTK2, EGFR, and TLRs were analyzed in NSCLC patients. To verify the functional association, we generated PTK2-knockout (PTK2-KO) lung cancer cells by using CRISPR-Cas9 gene editing method, and performed in vitro cancer progression assay, including 3D tumor spheroid assay, and in vivo xenografted NSG (NOD/SCID/IL-2Rγ ^null) mouse assay. Finally, therapeutic effects targeted to PTK2 in lung cancer in response to EGF and TLR agonists were verified by using its inhibitor (Defactinib). In summary, we identified that up-regulated PTK2 might be a reliable marker for EGFR- or TLRs-induced lung cancer progression in NSCLC patients via the regulation of the cross-talk between EGFR- and TLRs-mediated signaling. This study provides a theoretical basis for the therapeutic intervention of PTK2 targeting EGFR- or TLRs-induced lung cancer progression.

논문정보

형식Research article
게재일2024년 05월 (BRIC 등록일 2024-06-03)
연구진국내 연구진
분야 의약학 > 면역의학

댓글 작성 로그인

CV 열람하기

연락처 보기